Aptevo Therapeutics (APVO) Competitors $2.24 +0.11 (+4.91%) As of 02:12 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock APVO vs. CLRB, CYCN, DWTX, KPRX, ADXN, GNPX, AEON, SNSE, TRAW, and CHROShould you be buying Aptevo Therapeutics stock or one of its competitors? The main competitors of Aptevo Therapeutics include Cellectar Biosciences (CLRB), Cyclerion Therapeutics (CYCN), Dogwood Therapeutics (DWTX), Kiora Pharmaceuticals (KPRX), Addex Therapeutics (ADXN), Genprex (GNPX), AEON Biopharma (AEON), Sensei Biotherapeutics (SNSE), Traws Pharma (TRAW), and Chromocell Therapeutics (CHRO). These companies are all part of the "pharmaceutical products" industry. Aptevo Therapeutics vs. Its Competitors Cellectar Biosciences Cyclerion Therapeutics Dogwood Therapeutics Kiora Pharmaceuticals Addex Therapeutics Genprex AEON Biopharma Sensei Biotherapeutics Traws Pharma Chromocell Therapeutics Aptevo Therapeutics (NASDAQ:APVO) and Cellectar Biosciences (NASDAQ:CLRB) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, risk, earnings, profitability, institutional ownership, valuation, media sentiment and analyst recommendations. Do analysts recommend APVO or CLRB? Aptevo Therapeutics currently has a consensus price target of $219,040.00, suggesting a potential upside of 9,756,692.87%. Cellectar Biosciences has a consensus price target of $375.00, suggesting a potential upside of 7,921.39%. Given Aptevo Therapeutics' stronger consensus rating and higher probable upside, equities research analysts clearly believe Aptevo Therapeutics is more favorable than Cellectar Biosciences.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Aptevo Therapeutics 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Cellectar Biosciences 0 Sell rating(s) 2 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.33 Is APVO or CLRB more profitable? Cellectar Biosciences' return on equity of -619.70% beat Aptevo Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Aptevo TherapeuticsN/A -779.42% -175.59% Cellectar Biosciences N/A -619.70%-158.04% Does the media refer more to APVO or CLRB? In the previous week, Cellectar Biosciences had 1 more articles in the media than Aptevo Therapeutics. MarketBeat recorded 1 mentions for Cellectar Biosciences and 0 mentions for Aptevo Therapeutics. Aptevo Therapeutics' average media sentiment score of 0.00 equaled Cellectar Biosciences'average media sentiment score. Company Overall Sentiment Aptevo Therapeutics Neutral Cellectar Biosciences Neutral Which has stronger earnings & valuation, APVO or CLRB? Aptevo Therapeutics has higher revenue and earnings than Cellectar Biosciences. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAptevo Therapeutics$3.11M0.55-$24.13MN/AN/ACellectar BiosciencesN/AN/A-$44.58M-$21.92-0.21 Do institutionals & insiders hold more shares of APVO or CLRB? 8.1% of Aptevo Therapeutics shares are owned by institutional investors. Comparatively, 16.4% of Cellectar Biosciences shares are owned by institutional investors. 0.0% of Aptevo Therapeutics shares are owned by insiders. Comparatively, 5.0% of Cellectar Biosciences shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth. Which has more risk & volatility, APVO or CLRB? Aptevo Therapeutics has a beta of 5.64, suggesting that its stock price is 464% more volatile than the S&P 500. Comparatively, Cellectar Biosciences has a beta of 0.42, suggesting that its stock price is 58% less volatile than the S&P 500. SummaryAptevo Therapeutics and Cellectar Biosciences tied by winning 5 of the 10 factors compared between the two stocks. Get Aptevo Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for APVO and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding APVO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart APVO vs. The Competition Export to ExcelMetricAptevo TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.71M$2.98B$5.46B$9.67BDividend YieldN/A2.46%3.99%4.14%P/E RatioN/A17.9229.9924.97Price / Sales0.55174.22375.5577.11Price / CashN/A41.8335.9458.58Price / Book0.037.308.165.68Net Income-$24.13M-$54.43M$3.25B$265.38M7 Day Performance-16.23%0.07%1.11%2.52%1 Month Performance-27.58%5.24%2.80%1.86%1 Year Performance-99.98%10.72%28.49%24.21% Aptevo Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)APVOAptevo Therapeutics1.8716 of 5 stars$2.25+4.9%$219,040.00+9,756,692.9%-100.0%$1.71M$3.11M0.0050News CoverageUpcoming EarningsCLRBCellectar Biosciences2.8133 of 5 stars$5.03-1.2%$375.00+7,355.3%-91.7%$9.21MN/A-0.2310News CoveragePositive NewsUpcoming EarningsGap UpCYCNCyclerion Therapeutics2.4471 of 5 stars$2.78-2.8%N/A-18.9%$9.18M$2.08M-2.4030Positive NewsEarnings ReportDWTXDogwood Therapeutics1.4513 of 5 stars$4.78+0.1%$10.00+109.4%N/A$9.12MN/A-0.265News CoveragePositive NewsGap UpKPRXKiora Pharmaceuticals3.4271 of 5 stars$2.93-2.0%$10.00+241.3%-28.9%$9.10M$16.02M-1.0110News CoverageEarnings ReportADXNAddex Therapeutics2.9153 of 5 stars$8.34-2.7%$30.00+259.7%+5.5%$9.08M$170.62K-24.5330Positive NewsGNPXGenprex1.3248 of 5 stars$0.26-3.7%N/A-85.1%$9.03MN/A0.0020AEONAEON Biopharma3.27 of 5 stars$0.79-0.1%$360.00+45,527.4%-99.0%$8.92MN/A4.385Upcoming EarningsSNSESensei Biotherapeutics4.7256 of 5 stars$7.00+0.3%$90.00+1,185.7%-43.2%$8.80MN/A-0.3040News CoveragePositive NewsEarnings ReportAnalyst ForecastAnalyst RevisionGap DownTRAWTraws Pharma0.3848 of 5 stars$1.62+2.5%N/AN/A$8.79M$230K-0.0517News CoveragePositive NewsCHROChromocell TherapeuticsN/A$1.34+6.3%N/A-81.2%$8.69MN/A-1.084Gap UpHigh Trading Volume Related Companies and Tools Related Companies CLRB Alternatives CYCN Alternatives DWTX Alternatives KPRX Alternatives ADXN Alternatives GNPX Alternatives AEON Alternatives SNSE Alternatives TRAW Alternatives CHRO Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:APVO) was last updated on 8/8/2025 by MarketBeat.com Staff From Our PartnersGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredAltucher: Trump’s Great Gain is startingNew Hampshire just launched a Strategic Crypto Reserve — and James Altucher says it’s the first sign that “Tru...Paradigm Press | SponsoredBREAKING: The House just passed 3 pro-crypto bills!THREE pro-crypto bills just passed the House! Now, experts believe altcoin season is officially here. Crypto 101 Media | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredHow high will gold surge?Weiss Gold Veteran Makes Shocking New Call Weiss expert Sean Brodrick went out on a limb last year and decl...Weiss Ratings | SponsoredGold Hit $3,500. Here’s What’s Next…Gold just smashed through $3,500—and some experts believe that’s only the beginning. With big banks like Goldm...Reagan Gold Group | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aptevo Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Aptevo Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
